Literature DB >> 3923997

The economic costs of schizophrenia. Implications for public policy.

G Andrews, W Hall, G Goldstein, H Lapsley, R Bartels, D Silove.   

Abstract

The direct and indirect costs associated with schizophrenia in Australia were calculated using the incidence approach and compared with similar costings of myocardial infarction in Australia and the United States. In Australia schizophrenia affects one-twelfth as many people as does myocardial infarction, yet costs half as much. This is because the stream of costs associated with each case of schizophrenia is six times the stream of costs associated with myocardial infarction. To illustrate the utility of this costing approach, the information was used to estimate the cost-benefit ratio likely to follow the introduction of social intervention strategies. The information also showed that Australian support for research in schizophrenia is inadequate when compared with that for myocardial infarction and quite out of proportion to the cost of schizophrenia to the community.

Entities:  

Mesh:

Year:  1985        PMID: 3923997     DOI: 10.1001/archpsyc.1985.01790290015001

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  11 in total

Review 1.  Neuropsychiatric rehabilitation for persistent mental illness.

Authors:  J Jaeger; E Douglas
Journal:  Psychiatr Q       Date:  1992

2.  Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.

Authors:  A Schotte; P F Janssen; W Gommeren; W H Luyten; P Van Gompel; A S Lesage; K De Loore; J E Leysen
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

3.  Clozapine: an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia.

Authors:  A Fitton; P Benfield
Journal:  Pharmacoeconomics       Date:  1993-08       Impact factor: 4.981

4.  Some aspects of the cost of schizophrenia in France.

Authors:  F Rouillon; M Toumi; G Y Dansette; J Benyaya; P Auquier
Journal:  Pharmacoeconomics       Date:  1997-06       Impact factor: 4.981

5.  A Markov process analysis comparing the cost effectiveness of maintenance therapy with citalopram versus standard therapy in major depression.

Authors:  M J Nuijten; M Hardens; E Souêtre
Journal:  Pharmacoeconomics       Date:  1995-08       Impact factor: 4.981

6.  The costs of schizophrenia in Puerto Rico.

Authors:  M Rubio-Stipec; B Stipec; G Canino
Journal:  J Ment Health Adm       Date:  1994

7.  Overview and emerging trends.

Authors:  Sandeep Grover; Ajit Avasthi; Subho Chakrabarti; Paramanand Kulhara
Journal:  Indian J Psychiatry       Date:  2005-10       Impact factor: 1.759

8.  [Costs of psychiatric treatment: a comparative approach to 3 categories of patients].

Authors:  W Fischer; L Barrelet
Journal:  Soz Praventivmed       Date:  1987

9.  Regional differences in mental health in Great Britain.

Authors:  G Lewis; M Booth
Journal:  J Epidemiol Community Health       Date:  1992-12       Impact factor: 3.710

Review 10.  An economic evaluation of schizophrenia--1991.

Authors:  R J Wyatt; I Henter; M C Leary; E Taylor
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  1995-08       Impact factor: 4.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.